Skip to main content
Equibles

UBS Group AG

Position in GMAB — Genmab A/S

CIK 1610520 ZURICH, V8
Back to GMAB Full portfolio

Position in GMAB

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$26,400,124
+$18,401,244 QoQ
Shares Held
961,053
+222.4% QoQ
Ownership
0.156%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#20
of 292 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 96% Shared 0% None 4%

Common Shares in GMAB Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. GMAB ranks #63 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in GMAB

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $26,400,124 961,053
2026-03-31 $7,998,880 298,132
2025-12-31 $5,673,082 184,191
2025-09-30 $2,520,153 82,170
2025-06-30 $10,017,350 484,867
2025-03-31 $10,592,818 541,002
2024-12-31 $30,070,955 1,440,870
2024-09-30 $1,473,721 60,448
2024-06-30 $1,568,312 62,408
2024-03-31 $1,486,646 49,704
2023-12-31 $1,507,973 47,361
2023-09-30 $1,716,378 48,664
2023-06-30 $2,760,362 72,622
2023-03-31 $2,462,102 65,204
2022-12-31 $2,413,751 56,955
2022-09-30 $1,208,279 37,606
2022-06-30 $1,394,762 42,929
2022-03-31 $2,472,178 68,330
2021-12-31 $2,581,883 65,265
2021-09-30 $3,020,456 69,118
2021-06-30 $1,981,969 48,542
2021-03-31 $1,530,632 46,623
2020-12-31 $967,301 23,790
2020-09-30 $735,641 20,094
2020-06-30 $456,226 13,462
2020-03-31 $121,291 5,724